Jazz Pharmaceuticals (JAZZ) Scheduled to Post Quarterly Earnings on Wednesday

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) is set to announce its earnings results after the market closes on Wednesday, May 1st. Analysts expect the company to announce earnings of $3.55 per share for the quarter. Jazz Pharmaceuticals has set its FY24 guidance at $18.15-$19.35 EPS and its FY 2024 guidance at 18.150-19.350 EPS.Investors interested in participating in the company's conference call can do so using this link.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its earnings results on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share for the quarter, missing analysts' consensus estimates of $4.44 by ($0.04). The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $1.01 billion. Jazz Pharmaceuticals had a return on equity of 31.27% and a net margin of 10.82%. On average, analysts expect Jazz Pharmaceuticals to post $16 EPS for the current fiscal year and $19 EPS for the next fiscal year.

Jazz Pharmaceuticals Trading Down 1.2 %

Shares of JAZZ stock traded down $1.35 during trading hours on Wednesday, hitting $108.32. 401,342 shares of the company's stock traded hands, compared to its average volume of 608,323. The company has a quick ratio of 1.85, a current ratio of 2.24 and a debt-to-equity ratio of 1.37. Jazz Pharmaceuticals has a 12 month low of $106.61 and a 12 month high of $146.70. The stock has a market cap of $6.82 billion, a PE ratio of 17.69, a price-to-earnings-growth ratio of 1.50 and a beta of 0.59. The stock's 50 day simple moving average is $119.26 and its 200 day simple moving average is $122.14.

Insider Buying and Selling

In related news, CFO Philip L. Johnson purchased 12,000 shares of the firm's stock in a transaction dated Friday, March 1st. The shares were purchased at an average price of $119.65 per share, with a total value of $1,435,800.00. Following the acquisition, the chief financial officer now directly owns 27,932 shares of the company's stock, valued at $3,342,063.80. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, CFO Philip L. Johnson acquired 12,000 shares of the stock in a transaction dated Friday, March 1st. The stock was purchased at an average cost of $119.65 per share, with a total value of $1,435,800.00. Following the completion of the purchase, the chief financial officer now owns 27,932 shares in the company, valued at approximately $3,342,063.80. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO Patricia Carr sold 1,936 shares of the firm's stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total transaction of $231,623.04. Following the completion of the sale, the chief accounting officer now directly owns 8,364 shares of the company's stock, valued at $1,000,668.96. The disclosure for this sale can be found here. 4.40% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts have commented on JAZZ shares. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $180.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, April 10th. Robert W. Baird began coverage on shares of Jazz Pharmaceuticals in a report on Wednesday, January 3rd. They set an "outperform" rating and a $160.00 price target for the company. HC Wainwright reduced their price objective on shares of Jazz Pharmaceuticals from $204.00 to $200.00 and set a "buy" rating on the stock in a research note on Thursday, March 14th. Truist Financial reissued a "buy" rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 20th. Finally, Barclays cut their price target on shares of Jazz Pharmaceuticals from $235.00 to $230.00 and set an "overweight" rating on the stock in a research report on Friday, March 1st. Two research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $195.08.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.